Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy

Ashesh B. Jani, Danny Spelbring, Russell J Hamilton, Michael J. Blend, Charles Pelizzari, Charles Brendler, Lani Krauz, Srinivasan Vijayakumar, Bipin Sapra, Ralph R. Weichselbaum

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The goal of this study was to evaluate the role of radioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen in modifying postprostatectomy prostate fossa clinical target volume (CTV) definition. Methods: The records of 25 postprostatectomy patients who received external-beam radiotherapy after prostatectomy and who underwent vessel-based RIS/planning CT registration were reviewed. For each patient, the CTV that would have been treated (CTVpre) before this registration was compared with that defined after the registration (CTVpost). In addition, using a standard dose of 66 Gy in 2-Gy fractions, the corresponding bladder and rectum dose volume histograms were compared using 2 endpoints: volume receiving ≥60 Gy (V60) and area under the curve (AUC). Results: The mean CTVpre vs. CTVpost volumes were 24.4 vs. 35.0 cm3, respectively (P = 0.032). The V60 results for CTVpre and CTVpost were 32.7 vs. 41.0 cm3, respectively, for the rectum (P = 0.168) and 33.9 vs. 46.6 cm3, respectively, for the bladder (P = 0.015). The AUC results for CTVpre and CTVpost were 4,027 vs. 4,516 Gy x cm 3, respectively, for the rectum (P = 0.396) and 4,782 vs. 5,561, respectively, for the bladder (P = 0.119). No Radiation Therapy Oncology Group grade 3, 4, or 5 (acute or late, gastrointestinal, or genitourinary) toxicity was observed. Two-year biochemical failure-free survival (with failure defined as 2 consecutive prostate-specific antigen rises above 0.2 ng/mL) was 87% for the cohort. Conclusion: Incorporating RIS uptake resulted in significant modifications in CTV definition. The consequences of these modifications on the rectum V60 or AUC or on the bladder AUC were not significant, although the bladder V60 did increase. However, observed toxicity was low, with acceptable short-term biochemical control, suggesting that treatment to the modified CTV was tolerable.

Original languageEnglish (US)
Pages (from-to)238-246
Number of pages9
JournalJournal of Nuclear Medicine
Volume45
Issue number2
StatePublished - Feb 1 2004

Fingerprint

Radioimmunodetection
Prostatectomy
Urinary Bladder
Radiotherapy
Rectum
Area Under Curve
Radiation Oncology
Prostate-Specific Antigen
Prostate
Survival

Keywords

  • Prostate cancer
  • Prostatectomy
  • Radioimmunoscintigraphy
  • Radiotherapy

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Jani, A. B., Spelbring, D., Hamilton, R. J., Blend, M. J., Pelizzari, C., Brendler, C., ... Weichselbaum, R. R. (2004). Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. Journal of Nuclear Medicine, 45(2), 238-246.

Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. / Jani, Ashesh B.; Spelbring, Danny; Hamilton, Russell J; Blend, Michael J.; Pelizzari, Charles; Brendler, Charles; Krauz, Lani; Vijayakumar, Srinivasan; Sapra, Bipin; Weichselbaum, Ralph R.

In: Journal of Nuclear Medicine, Vol. 45, No. 2, 01.02.2004, p. 238-246.

Research output: Contribution to journalArticle

Jani, AB, Spelbring, D, Hamilton, RJ, Blend, MJ, Pelizzari, C, Brendler, C, Krauz, L, Vijayakumar, S, Sapra, B & Weichselbaum, RR 2004, 'Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy', Journal of Nuclear Medicine, vol. 45, no. 2, pp. 238-246.
Jani, Ashesh B. ; Spelbring, Danny ; Hamilton, Russell J ; Blend, Michael J. ; Pelizzari, Charles ; Brendler, Charles ; Krauz, Lani ; Vijayakumar, Srinivasan ; Sapra, Bipin ; Weichselbaum, Ralph R. / Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. In: Journal of Nuclear Medicine. 2004 ; Vol. 45, No. 2. pp. 238-246.
@article{32046b9ff6614b6ca8d256ab127aedae,
title = "Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy",
abstract = "The goal of this study was to evaluate the role of radioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen in modifying postprostatectomy prostate fossa clinical target volume (CTV) definition. Methods: The records of 25 postprostatectomy patients who received external-beam radiotherapy after prostatectomy and who underwent vessel-based RIS/planning CT registration were reviewed. For each patient, the CTV that would have been treated (CTVpre) before this registration was compared with that defined after the registration (CTVpost). In addition, using a standard dose of 66 Gy in 2-Gy fractions, the corresponding bladder and rectum dose volume histograms were compared using 2 endpoints: volume receiving ≥60 Gy (V60) and area under the curve (AUC). Results: The mean CTVpre vs. CTVpost volumes were 24.4 vs. 35.0 cm3, respectively (P = 0.032). The V60 results for CTVpre and CTVpost were 32.7 vs. 41.0 cm3, respectively, for the rectum (P = 0.168) and 33.9 vs. 46.6 cm3, respectively, for the bladder (P = 0.015). The AUC results for CTVpre and CTVpost were 4,027 vs. 4,516 Gy x cm 3, respectively, for the rectum (P = 0.396) and 4,782 vs. 5,561, respectively, for the bladder (P = 0.119). No Radiation Therapy Oncology Group grade 3, 4, or 5 (acute or late, gastrointestinal, or genitourinary) toxicity was observed. Two-year biochemical failure-free survival (with failure defined as 2 consecutive prostate-specific antigen rises above 0.2 ng/mL) was 87{\%} for the cohort. Conclusion: Incorporating RIS uptake resulted in significant modifications in CTV definition. The consequences of these modifications on the rectum V60 or AUC or on the bladder AUC were not significant, although the bladder V60 did increase. However, observed toxicity was low, with acceptable short-term biochemical control, suggesting that treatment to the modified CTV was tolerable.",
keywords = "Prostate cancer, Prostatectomy, Radioimmunoscintigraphy, Radiotherapy",
author = "Jani, {Ashesh B.} and Danny Spelbring and Hamilton, {Russell J} and Blend, {Michael J.} and Charles Pelizzari and Charles Brendler and Lani Krauz and Srinivasan Vijayakumar and Bipin Sapra and Weichselbaum, {Ralph R.}",
year = "2004",
month = "2",
day = "1",
language = "English (US)",
volume = "45",
pages = "238--246",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "2",

}

TY - JOUR

T1 - Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy

AU - Jani, Ashesh B.

AU - Spelbring, Danny

AU - Hamilton, Russell J

AU - Blend, Michael J.

AU - Pelizzari, Charles

AU - Brendler, Charles

AU - Krauz, Lani

AU - Vijayakumar, Srinivasan

AU - Sapra, Bipin

AU - Weichselbaum, Ralph R.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - The goal of this study was to evaluate the role of radioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen in modifying postprostatectomy prostate fossa clinical target volume (CTV) definition. Methods: The records of 25 postprostatectomy patients who received external-beam radiotherapy after prostatectomy and who underwent vessel-based RIS/planning CT registration were reviewed. For each patient, the CTV that would have been treated (CTVpre) before this registration was compared with that defined after the registration (CTVpost). In addition, using a standard dose of 66 Gy in 2-Gy fractions, the corresponding bladder and rectum dose volume histograms were compared using 2 endpoints: volume receiving ≥60 Gy (V60) and area under the curve (AUC). Results: The mean CTVpre vs. CTVpost volumes were 24.4 vs. 35.0 cm3, respectively (P = 0.032). The V60 results for CTVpre and CTVpost were 32.7 vs. 41.0 cm3, respectively, for the rectum (P = 0.168) and 33.9 vs. 46.6 cm3, respectively, for the bladder (P = 0.015). The AUC results for CTVpre and CTVpost were 4,027 vs. 4,516 Gy x cm 3, respectively, for the rectum (P = 0.396) and 4,782 vs. 5,561, respectively, for the bladder (P = 0.119). No Radiation Therapy Oncology Group grade 3, 4, or 5 (acute or late, gastrointestinal, or genitourinary) toxicity was observed. Two-year biochemical failure-free survival (with failure defined as 2 consecutive prostate-specific antigen rises above 0.2 ng/mL) was 87% for the cohort. Conclusion: Incorporating RIS uptake resulted in significant modifications in CTV definition. The consequences of these modifications on the rectum V60 or AUC or on the bladder AUC were not significant, although the bladder V60 did increase. However, observed toxicity was low, with acceptable short-term biochemical control, suggesting that treatment to the modified CTV was tolerable.

AB - The goal of this study was to evaluate the role of radioimmunoscintigraphy (RIS) directed against prostate-specific membrane antigen in modifying postprostatectomy prostate fossa clinical target volume (CTV) definition. Methods: The records of 25 postprostatectomy patients who received external-beam radiotherapy after prostatectomy and who underwent vessel-based RIS/planning CT registration were reviewed. For each patient, the CTV that would have been treated (CTVpre) before this registration was compared with that defined after the registration (CTVpost). In addition, using a standard dose of 66 Gy in 2-Gy fractions, the corresponding bladder and rectum dose volume histograms were compared using 2 endpoints: volume receiving ≥60 Gy (V60) and area under the curve (AUC). Results: The mean CTVpre vs. CTVpost volumes were 24.4 vs. 35.0 cm3, respectively (P = 0.032). The V60 results for CTVpre and CTVpost were 32.7 vs. 41.0 cm3, respectively, for the rectum (P = 0.168) and 33.9 vs. 46.6 cm3, respectively, for the bladder (P = 0.015). The AUC results for CTVpre and CTVpost were 4,027 vs. 4,516 Gy x cm 3, respectively, for the rectum (P = 0.396) and 4,782 vs. 5,561, respectively, for the bladder (P = 0.119). No Radiation Therapy Oncology Group grade 3, 4, or 5 (acute or late, gastrointestinal, or genitourinary) toxicity was observed. Two-year biochemical failure-free survival (with failure defined as 2 consecutive prostate-specific antigen rises above 0.2 ng/mL) was 87% for the cohort. Conclusion: Incorporating RIS uptake resulted in significant modifications in CTV definition. The consequences of these modifications on the rectum V60 or AUC or on the bladder AUC were not significant, although the bladder V60 did increase. However, observed toxicity was low, with acceptable short-term biochemical control, suggesting that treatment to the modified CTV was tolerable.

KW - Prostate cancer

KW - Prostatectomy

KW - Radioimmunoscintigraphy

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=1542399602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542399602&partnerID=8YFLogxK

M3 - Article

C2 - 14960642

AN - SCOPUS:1542399602

VL - 45

SP - 238

EP - 246

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 2

ER -